Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00045747 · ClinicalTrials.gov registry record · Phase 2
UCN-01 and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00045747: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00045747 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00045747, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: UCN-01 may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining UCN-01 with chemotherapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining UCN-01 with fluorouracil in treating patients who have metastatic pancreatic cancer that has not responded to treatment with gemcitabine.
Interventions
- DRUG fluorouracil
- DRUG 7-hydroxystaurosporine
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-07 |
| Est. Completion | 2004-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00045747
The ClinicalTrials.gov registry entry for NCT00045747 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which fluorouracil is the first listed.
NCT00045747 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00045747 about?
NCT00045747 is a clinical study titled "UCN-01 and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer". RATIONALE: UCN-01 may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining UCN-01 with chemotherapy may kill more tumor cells. PURPOSE: Phase II ...
What is the current status of trial NCT00045747?
This trial is currently completed. It is a Phase 2 study. The study started on 2002-07. Estimated completion is 2004-09.
What interventions are being tested in trial NCT00045747?
The interventions under investigation include: fluorouracil (DRUG), 7-hydroxystaurosporine (DRUG).
Who is sponsoring clinical trial NCT00045747?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.